This post was originally published on this site

Equities analysts expect IntriCon Co. (NASDAQ:IIN) to report $27.33 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for IntriCon’s earnings, with the lowest sales estimate coming in at $27.10 million and the highest estimate coming in at $27.55 million. IntriCon reported sales of $27.69 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 1.3%. The firm is scheduled to announce its next quarterly earnings results on Monday, February 22nd.

On average, analysts expect that IntriCon will report full year sales of $99.81 million for the current financial year, with estimates ranging from $99.60 million to $100.02 million. For the next year, analysts expect that the business will report sales of $117.57 million, with estimates ranging from $113.60 million to $121.54 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover IntriCon.

IntriCon (NASDAQ:IIN) last announced its quarterly earnings data on Monday, November 9th. The technology company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.12. The business had revenue of $27.37 million during the quarter, compared to analysts’ expectations of $24.57 million. IntriCon had a negative net margin of 2.84% and a negative return on equity of 0.80%.

NASDAQ IIN traded down $0.30 on Friday, reaching $17.75. 17,768 shares of the company’s stock traded hands, compared to its average volume of 24,554. IntriCon has a fifty-two week low of $9.84 and a fifty-two week high of $19.70. The firm has a market cap of $158.74 million, a price-to-earnings ratio of -53.79 and a beta of 1.23. The stock has a 50 day moving average price of $17.44 and a 200-day moving average price of $13.85.

In related news, VP Michael Geraci sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 14th. The stock was sold at an average price of $16.83, for a total transaction of $126,225.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 10.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in IIN. JPMorgan Chase & Co. raised its stake in shares of IntriCon by 24.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,428 shares of the technology company’s stock worth $102,000 after buying an additional 1,650 shares during the period. Royce & Associates LP raised its position in IntriCon by 9.6% during the third quarter. Royce & Associates LP now owns 772,777 shares of the technology company’s stock worth $9,412,000 after acquiring an additional 67,483 shares during the period. Palisade Capital Management LLC NJ lifted its holdings in IntriCon by 4.5% during the third quarter. Palisade Capital Management LLC NJ now owns 473,221 shares of the technology company’s stock valued at $5,764,000 after purchasing an additional 20,354 shares in the last quarter. Acuitas Investments LLC grew its position in shares of IntriCon by 38.2% in the third quarter. Acuitas Investments LLC now owns 140,309 shares of the technology company’s stock valued at $1,709,000 after purchasing an additional 38,751 shares during the period. Finally, Gamco Investors INC. ET AL increased its stake in shares of IntriCon by 13.3% during the third quarter. Gamco Investors INC. ET AL now owns 541,423 shares of the technology company’s stock worth $6,595,000 after purchasing an additional 63,673 shares in the last quarter. 67.93% of the stock is currently owned by hedge funds and other institutional investors.

About IntriCon

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-End-Consumer. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.

Recommended Story: What is the price-sales ratio?

Get a free copy of the Zacks research report on IntriCon (IIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IntriCon Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IntriCon and related companies with MarketBeat.com’s FREE daily email newsletter.